1. Home
  2. BBW vs ALLO Comparison

BBW vs ALLO Comparison

Compare BBW & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBW
  • ALLO
  • Stock Information
  • Founded
  • BBW 1997
  • ALLO 2017
  • Country
  • BBW United States
  • ALLO United States
  • Employees
  • BBW N/A
  • ALLO N/A
  • Industry
  • BBW Recreational Games/Products/Toys
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BBW Consumer Discretionary
  • ALLO Health Care
  • Exchange
  • BBW Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • BBW 464.1M
  • ALLO 371.8M
  • IPO Year
  • BBW 2004
  • ALLO 2018
  • Fundamental
  • Price
  • BBW $40.49
  • ALLO $1.11
  • Analyst Decision
  • BBW Strong Buy
  • ALLO Strong Buy
  • Analyst Count
  • BBW 4
  • ALLO 10
  • Target Price
  • BBW $50.50
  • ALLO $8.90
  • AVG Volume (30 Days)
  • BBW 226.3K
  • ALLO 4.1M
  • Earning Date
  • BBW 05-29-2025
  • ALLO 05-13-2025
  • Dividend Yield
  • BBW 2.18%
  • ALLO N/A
  • EPS Growth
  • BBW 4.11
  • ALLO N/A
  • EPS
  • BBW 3.80
  • ALLO N/A
  • Revenue
  • BBW $496,404,000.00
  • ALLO N/A
  • Revenue This Year
  • BBW $5.54
  • ALLO N/A
  • Revenue Next Year
  • BBW $3.77
  • ALLO $9.07
  • P/E Ratio
  • BBW $10.63
  • ALLO N/A
  • Revenue Growth
  • BBW 2.12
  • ALLO N/A
  • 52 Week Low
  • BBW $23.63
  • ALLO $0.86
  • 52 Week High
  • BBW $48.23
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • BBW 58.21
  • ALLO 38.30
  • Support Level
  • BBW $40.53
  • ALLO $1.07
  • Resistance Level
  • BBW $42.56
  • ALLO $1.15
  • Average True Range (ATR)
  • BBW 1.38
  • ALLO 0.14
  • MACD
  • BBW 0.43
  • ALLO -0.01
  • Stochastic Oscillator
  • BBW 65.04
  • ALLO 27.17

About BBW Build-A-Bear Workshop Inc.

Build-A-Bear Workshop Inc is a U.S.-based specialty retailer of customized stuffed animals and related products. The company operates through three segments. Its Direct-to-consumer segment with key revenue, includes the operating activities of corporately-managed locations and other retail delivery operations in the U.S., Canada, China, Denmark, Ireland, and the U.K., including the company's e-commerce sites and temporary stores. The international franchising segment includes the licensing activities of the company's franchise agreements with store locations in Europe, Asia, Australia, the Middle East, and Africa. The commercial segment includes the transactions with other businesses, mainly comprised of licensing the intellectual properties for third-party use and wholesale activities.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: